Evidence map›Paper›PMID 26943906›Full record

ArticlePloS one2016

Three Recombinant Engineered Antibodies against Recombinant Tags with High Affinity and Specificity.

Hongyu Zhao, Ao Shen, Yang K Xiang, David P Corey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hongyu ZhaoDepartment of Neurobiology and Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
Ao ShenDepartment of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.
Yang K XiangDepartment of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.
David P CoreyDepartment of Neurobiology and Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
University of California, Davis · USHarvard University · USHoward Hughes Medical Institute · US

Funding

Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SAHIN, MUSTAFA · 2016 to 2020
$5.2M
MOLECULAR BASIS OF INHERITED DEAFNESSR01DC002281 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI COREY, DAVID P · 1994 to 2018
$4.4M
Spatiotemporal regulation of beta adrenoceptor signaling in cardiacmyocytesR01HL082846 · NHLBI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI XIANG, YANG K · 2006 to 2014
$3.0M
Howard Hughes Medical InstituteNHLBI NIH HHS HL082846NHLBI NIH HHS R01 HL082846NICHD NIH HHS U54 HD090255NIDCD NIH HHS DC002281NIDCD NIH HHS R01 DC002281
6 · The paper itself

Abstract

We describe three recombinant engineered antibodies against three recombinant epitope tags, constructed with divalent binding arms to recognize divalent epitopes and so achieve high affinity and specificity. In two versions, an epitope is inserted in tandem into a protein of interest, and a homodimeric antibody is constructed by fusing a high-affinity epitope-binding domain to a human or mouse Fc domain. In a third, a heterodimeric antibody is constructed by fusing two different epitope-binding domains which target two different binding sites in GFP, to polarized Fc fragments. These antibody/epitope pairs have affinities in the low picomolar range and are useful tools for many antibody-based applications.

Indexed as

AnimalsAntibodies, BispecificAntibody SpecificityEpitopesGreen Fluorescent ProteinsHEK293 CellsHumansMicePeptidesProtein BindingProtein EngineeringProtein MultimerizationRecombinant Fusion ProteinsRecombinant ProteinsAntibodies, BispecificEpitopesGreen Fluorescent ProteinsPeptidesRecombinant Fusion ProteinsRecombinant Proteins

Identifiers

PMID26943906
PMCPMC4778845
OpenAlexW2290965507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.